Role of the primary care provider in the diagnosis and management of heartburn

References

• Richter JE. The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment. Gastroenterol Clin North Am 2007;36:577-99
   PubMed Web of Science ®Google Scholar
• Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20
   PubMed Web of Science ®Google Scholar
• Locke III GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56
   PubMed Web of Science ®Google Scholar
• Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005;3:543-52
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Christos PJ, Talley NJ, et al. Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med 1999;159:1592-8
   PubMed Web of Science ®Google Scholar
• Naliboff BD, Mayer M, Fass R, et al. The effect of life stress on symptoms of heartburn. Psychosom Med 2004;66:426-34
   PubMed Web of Science ®Google Scholar
• McCarthy D. Living with chronic heartburn: insights into its debilitating effects. Gastroenterol Clin North Am 2003;32:S1-S9
   PubMed Web of Science ®Google Scholar
• Calleja JL, Bixquert M, Maldonado J. Impact of nocturnal heartburn on quality of life, sleep, and productivity: the SINERGE study. Dig Dis Sci 2007;52:2858-65
   PubMed Web of Science ®Google Scholar
• Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001;161:45-52
   PubMed Web of Science ®Google Scholar
• Ang D, Sifrim D, Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol 2008;5:383-92
   PubMedGoogle Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-413
   PubMed Web of Science ®Google Scholar
• Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000;45:809-18
   PubMed Web of Science ®Google Scholar
• Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-37
   PubMed Web of Science ®Google Scholar
• Pace F, Casini V, Pallotta S. Heterogeneity of endoscopy negative heartburn: Epidemiology and natural history. World J Gastroenterol 2008;14:5233-6
   PubMed Web of Science ®Google Scholar
• Editorial. Diagnosis and treatment of GERD. Drug Utilization in Practice 2007;16:1-3
   Google Scholar
• Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97
   PubMed Web of Science ®Google Scholar
• Talley NJ. What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2004;20(Suppl 2):23-30
   PubMedGoogle Scholar
• Zimmermann AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacotherapy 1997;17:308-26
   PubMed Web of Science ®Google Scholar
• Lacy BE, Cash BD. A 32-year-old woman with chronic abdominal pain. JAMA 2008;299:555-65
   PubMed Web of Science ®Google Scholar
• Zweber A, Berardi RR. Heartburn and dyspepsia. In: Berardi RR, ed. Handbook of Nonprescription Drugs: An interactive Approach to Self-Care. Washington, DC: American Pharmacists Association; 2009
   Google Scholar
• Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008;359:1700-7
   PubMed Web of Science ®Google Scholar
• Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008;27:249-56
   PubMed Web of Science ®Google Scholar
• Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000;18:20-6
   PubMed Web of Science ®Google Scholar
• Katz PO. Is it worthwhile performing a PPI trial in primary-care patients with GERD symptoms?. Nat Clin Pract Gastroenterol Hepatol 2007;4:252-3
   PubMedGoogle Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-91
   PubMed Web of Science ®Google Scholar
• Tutuian R. Update in the diagnosis of gastroesophageal reflux disease. J Gastrointestin Liver Dis 2006;15:243-7
   PubMedGoogle Scholar
• Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965-71
   PubMed Web of Science ®Google Scholar
• Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci 2005;27:432-5
   PubMed Web of Science ®Google Scholar
• Sax MJ. Clinically important adverse effects and drug interactions with H2-receptor antagonists: an update. Pharmacotherapy 1987;7:110-15S
   Web of Science ®Google Scholar
• Gill SK, O'Brien L, Koren G. The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig Dis Sci 2009;54:1835-8
   PubMed Web of Science ®Google Scholar
• Cezard JP. Managing gastro-oesophageal reflux disease in children. Digestion 2004;69(Suppl 1):3-8
   PubMed Web of Science ®Google Scholar
• Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician 2002;66:273-80
   PubMed Web of Science ®Google Scholar
• Dowswell T, Neilson JP. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev 2008;CD007065
   Google Scholar
• Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):9-14
   PubMedGoogle Scholar
• Allgood LD, Grender JM, Shaw MJ, et al. Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn. J Clin Pharm Ther 2005;30:105-12
   PubMed Web of Science ®Google Scholar
• Baldi F, Morselli-Labate AM, Cappiello R, et al. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol 2002;97:1357-64
   PubMed Web of Science ®Google Scholar
• Peura DA, Gudmundson J, Siepman N, et al. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 2007;52:983-7
   PubMed Web of Science ®Google Scholar
• Miner PB Jr, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Aliment Pharmacol Ther 2007;25:103-9
   PubMed Web of Science ®Google Scholar
• Devault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200
   PubMed Web of Science ®Google Scholar
• Johnson DA, Katz PO. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord 2008;8:98-108
   PubMed Web of Science ®Google Scholar
• Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78
   PubMed Web of Science ®Google Scholar
• Peura DA, Riff D, Snoddy AM, et al. Clinical trial: lansoprazole 15 or 30 mg once daily vs placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther 2009;30:459-68
   PubMed Web of Science ®Google Scholar
• Cote GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:208-14
   PubMedGoogle Scholar
• Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63:2739-54
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 2009;17:198-200
   PubMed Web of Science ®Google Scholar
• Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2009; Nov 10. 1-8 [Epub ahead of print]
   Google Scholar
• US Department of Health and Human Services. Information for Healthcare Professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Washington, DC: US Department of Health and Human Services;2009
   Google Scholar
• Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-26
   PubMed Web of Science ®Google Scholar
• Graber M, Dachs R, Darby-Stewart A. Long-term PPI therapy and the risk of hip fracture. Am Family Physician 2008;77:277-8
   Web of Science ®Google Scholar
• Metz DC. Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor. Am J Gastroenterol 2008;103:2314-16
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
   PubMed Web of Science ®Google Scholar
• National Institutes of Health, US Department of Health and Human Services. Dietary supplement fact sheet: vitamin D. 4-18-2008. Bethesda, MD: National Institutes of Health, 2008
   Google Scholar
• Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000;39:295-309
   PubMed Web of Science ®Google Scholar
• Sanger GJ. 5-hydroxytryptamine and the gastrointestinal tract: where next?. Trends Pharmacol Sci 2008;29:465-71
   PubMed Web of Science ®Google Scholar